ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
ADMA Biologics cash
Cash and short-term investments held at the end of each period.
ADMA Biologics's cash was $124.56M at Sep 30, 2026. For fiscal 2025 it was $87.63M, down 15.0% from the year before. Over ten years it grew 18.0% a year on average. The highest annual figure on record is $103.15M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.63M | -15.0% |
| FY2024 | Dec 31, 2024 | $103.15M | +100.9% |
| FY2023 | Dec 31, 2023 | $51.35M | -40.6% |
| FY2022 | Dec 31, 2022 | $86.52M | +69.4% |
| FY2021 | Dec 31, 2021 | $51.09M | -8.6% |
| FY2020 | Dec 31, 2020 | $55.92M | +109.0% |
| FY2019 | Dec 31, 2019 | $26.75M | -0.0% |
| FY2018 | Dec 31, 2018 | $26.75M | -45.0% |
| FY2017 | Dec 31, 2017 | $48.61M | +217.6% |
| FY2016 | Dec 31, 2016 | $15.31M | -8.9% |
| FY2015 | Dec 31, 2015 | $16.81M | -23.1% |
| FY2014 | Dec 31, 2014 | $21.85M | -24.9% |
| FY2013 | Dec 31, 2013 | $29.08M | +132.0% |
| FY2012 | Dec 31, 2012 | $12.54M | +14182.2% |
| FY2011 | Dec 31, 2011 | $87.77K | -61.7% |
| FY2010 | Dec 31, 2010 | $228.97K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $124.56M | +102.9% |
| Q2 FY2026 | Jun 30, 2026 | $136.02M | +50.7% |
| Q1 FY2026 | Mar 31, 2026 | $138.15M | +92.9% |
| Q4 FY2025 | Dec 31, 2025 | $87.63M | -15.0% |
| Q3 FY2025 | Sep 30, 2025 | $61.39M | -29.2% |
| Q2 FY2025 | Jun 30, 2025 | $90.29M | +2.3% |
| Q1 FY2025 | Mar 31, 2025 | $71.63M | +58.0% |
| Q4 FY2024 | Dec 31, 2024 | $103.15M | +100.9% |
| Q3 FY2024 | Sep 30, 2024 | $86.71M | +16.9% |
| Q2 FY2024 | Jun 30, 2024 | $88.24M | +41.2% |
| Q1 FY2024 | Mar 31, 2024 | $45.33M | -34.5% |
| Q4 FY2023 | Dec 31, 2023 | $51.35M | -40.6% |
| Q3 FY2023 | Sep 30, 2023 | $74.16M | +112.4% |
| Q2 FY2023 | Jun 30, 2023 | $62.51M | +19.3% |
| Q1 FY2023 | Mar 31, 2023 | $69.20M | -0.4% |
| Q4 FY2022 | Dec 31, 2022 | $86.52M | +69.4% |
| Q3 FY2022 | Sep 30, 2022 | $34.91M | +1.4% |
| Q2 FY2022 | Jun 30, 2022 | $52.42M | +23.6% |
| Q1 FY2022 | Mar 31, 2022 | $69.50M | +12.2% |
| Q4 FY2021 | Dec 31, 2021 | $51.09M | -8.6% |
| Q3 FY2021 | Sep 30, 2021 | $34.41M | -42.3% |
| Q2 FY2021 | Jun 30, 2021 | $42.41M | -44.0% |
| Q1 FY2021 | Mar 31, 2021 | $61.97M | -38.8% |
| Q4 FY2020 | Dec 31, 2020 | $55.92M | +109.0% |
| Q3 FY2020 | Sep 30, 2020 | $59.68M | +24.3% |
| Q2 FY2020 | Jun 30, 2020 | $75.78M | +2.9% |
| Q1 FY2020 | Mar 31, 2020 | $101.24M | +512.3% |
| Q4 FY2019 | Dec 31, 2019 | $26.75M | -0.0% |
| Q3 FY2019 | Sep 30, 2019 | $48.01M | +3.5% |
| Q2 FY2019 | Jun 30, 2019 | $73.62M | +24.4% |
| Q1 FY2019 | Mar 31, 2019 | $16.53M | -47.7% |
| Q4 FY2018 | Dec 31, 2018 | $26.75M | -45.0% |
| Q3 FY2018 | Sep 30, 2018 | $46.37M | +240.9% |
| Q2 FY2018 | Jun 30, 2018 | $59.15M | +131.3% |
| Q1 FY2018 | Mar 31, 2018 | $31.62M | +259.8% |
| Q4 FY2017 | Dec 31, 2017 | $48.61M | +217.6% |
| Q3 FY2017 | Sep 30, 2017 | $13.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $25.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $15.31M | – |
See a number that looks wrong?